ReviewJHEP reports : innovation in hepatology2025
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment.
Review in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.Nature communications · 2025Trial
- Endocrine meets hepatic: the thyroid-liver axis in health and disease-an overview.Wiener medizinische Wochenschrift (1946) · 2026Review
- The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH.International journal of molecular sciences · 2026Review
- Magnetic resonance imaging findings after stereotactic body radiation therapy for hepatocellular carcinoma - a scoping literature review.Clinical and translational radiation oncology · 2026Review
- Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Article
- Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Review
- Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study.European radiology · 2026Article
- Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.Hepatology international · 2026Article
- Characterisation of liver disease using quantitative MRI: report of the imaging arm of the ELEGANCE study.BMC gastroenterology · 2026Article
- Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Nature reviews. Clinical oncology · 2026Article
- First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.Journal of clinical medicine · 2026Article
- Article
- Review
- Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- Beyond VEGF: AEG-1/MTDH as a Systems-Level Orchestrator of Angiogenesis in Hepatocellular Carcinoma.Cells · 2026Review
- Glycoproteome Profiling of Human Serum for Hepatocellular Carcinoma Biomarker Discovery.Journal of proteome research · 2026Article
- N-glycosylation of ERLIN2 promotes hepatocellular carcinoma progression by enhancing CCNB1 stability.Molecular and cellular biochemistry · 2026Article
- SDF4: a novel prognostic biomarker and therapeutic target in hepatocellular carcinoma revealed by integrated multi‑omics analysis.Translational cancer research · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and primarily affects individuals with cirrhosis. While viral hepatitis has historically been the predominant cause, the burden of HCC is increasingly shifting toward non-viral aetiologies, such as ALD (alcohol-related liver disease) and MASLD (metabolic dysfunction-associated steatotic liver disease). Preventive strategies, including HBV vaccination and antiviral therapies, have reduced the incidence of virus-related HCC, while emerging antifibrotic and metabolic agents may limit MASLD progression. Surveillance with biannual ultrasound and alpha-fetoprotein testing facilitates early detection and curative treatment, although underuse remains a critical limitation. Advances in surgical resection, liver transplantation, and locoregional therapies have improved outcomes in early and intermediate stages. In advanced HCC, immune checkpoint inhibitor-based combinations have shifted the treatment landscape, with median overall survival now exceeding two years and long-term responses observed in a subset of patients. Despite these advances, substantial unmet needs remain in prevention, early detection, and therapeutic access. Ongoing research into biomarkers and novel treatments offers the potential to further transform the HCC care continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.